Checkpoint inhibitor prolongs survival with certain head and neck cancers

Compared to the standard therapy, survival was significantly improved for participants with previously untreated recurrent or metastatic head and neck cancers.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news